A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia.

Trial Profile

A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
    • 16 May 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 13 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top